利索-全球专利检索

  1. 登录
  2. 注册

搜索结果

12 条记录 (耗时 0.024 秒)

    PEPTIDES FOR USE IN THE TOPICAL TREATMENT OF RETINAL NEURODEGENERATIVE DISESASES, IN PARTICULAR IN EARLY STAGES OF DIABETIC RETINOPATHY AND OTHER RETINAL DISEASES IN WHICH NEURODEGENERATION PLAYS AN ESSENTIAL ROLE
    5.
    发明公开
    PEPTIDES FOR USE IN THE TOPICAL TREATMENT OF RETINAL NEURODEGENERATIVE DISESASES, IN PARTICULAR IN EARLY STAGES OF DIABETIC RETINOPATHY AND OTHER RETINAL DISEASES IN WHICH NEURODEGENERATION PLAYS AN ESSENTIAL ROLE 有权
    肽FOR USE IN局部治疗视网膜的神经退行性疾病，尤其是糖尿病性视网膜病变和/或电源皮肤疾病的早期阶段与神经变性的一个重要因素

    公开(公告)号：EP2968471A1

    公开(公告)日：2016-01-20

    申请号：EP14707980.0

    申请日：2014-02-27

    申请人： Fundació Hospital Universitari Vall d'Hebron - Institut de Recerca

    发明人： SIMÓ CANONGE, Rafael ,  HERNÁNDEZ PASCUAL, Cristina

    IPC分类号： A61K38/26 ,  A61K9/00 ,  C07K14/605 ,  A61P27/02 ,  A61P27/06

    CPC分类号： A61K38/26 ,  A61K9/0048 ,  A61K38/10 ,  C07K14/605

    摘要： The invention relates to peptides with a sequence length from 13 to 50 amino acids, the N-terminal region of said peptides consisting in the sequence HXaa
    1 EGTFTSDXaa
    2 SXaa
    3 Xaa
    4 (SEQ ID NO: 1 ) wherein: Xaa
    1 is an amino acid selected from alanine and glycine; Xaa
    2 is an amino acid selected from valine and leucine; Xaa
    3 is an amino acid selected from serine and lysine; Xaa
    4 is an amino acid selected from tyrosine and glutamine; and Hystidine is the N-terminal residue; for use in the topical treatment and/or prevention of retinal neurodegenerative diseases, in particular diabetic retinopathy. The invention also encompasses pharmaceutical topical compositions for use in the topical treatment and/or prevention of these diseases.

    摘要翻译： 本发明涉及从13至50个氨基酸的序列长度的肽，所述肽在序列HXaa1EGTFTSDXaa2SXaa3Xaa4由...组成的N-末端区（SEQ ID NO：1）worin：Xaa1是选自丙氨酸和甘氨酸的氨基酸; Xaa 2是选自缬氨酸和亮氨酸的氨基酸; Xaa3是由丝氨酸和赖氨酸的氨基酸; 的Xaa 4是选自酪氨酸和谷氨酰胺的氨基酸; 和组氨酸是N-末端残基; 用于局部治疗和/或预防神经变性的视网膜疾病，特别是糖尿病性视网膜病中的用途。 因此，本发明包括一种用于在疾病论文的局部治疗和/或预防用途的药物局部用组合物。